Now showing items 1-3 of 3

    • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 

      Bigner, DD; Boulton, ST; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, James Emmett II; ... (17 authors) (Br J Cancer, 2012-10-23)
      BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation ...
    • c-Myc is required for maintenance of glioma cancer stem cells. 

      Hjelmeland, AB; Lathia, JD; Li, Z; McLendon, Roger E; Rich, JN; Wang, H; Wang, J; ... (8 authors) (PLoS One, 2008)
      BACKGROUND: Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in ...
    • Targeting A20 decreases glioma stem cell survival and tumor growth. 

      Eyler, C; Heddleston, J; Hjelmeland, AB; Lathia, JD; Lee, J; Macswords, J; McLendon, Roger E; ... (11 authors) (PLoS Biol, 2010-02-23)
      Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs). GSCs are regulated by molecular pathways distinct from the bulk tumor that may be ...